Abstracts tagged "Intervention"

Abstract Number: 2324 • 2016 ACR/ARHP Annual Meeting
Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis
Anders Nørkjær Jørgensen¹, Per Aagaard¹, Mette Christiansen¹, Ulrik Frandsen¹ and Louise Pyndt Diederichsen², ¹University of Southern Denmark, Odense, Denmark, ²Rheumatology, Odense University Hospital, Odense, Denmark
Background/Purpose: Sporadic inclusion body myositis (sIBM) represents a progressive inflammatory muscle disease, which causes severe loss in skeletal muscle mass and strength, especially in the…
Abstract Number: 3138 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment
Edmond Ramly^1,2, Daniel Panyard³, Diane Lauver⁴, Emmanuel Sampene⁵, Zhanhai Li⁵, Heather Johnson⁶, Patrick McBride⁶, Kristin Steffen Lewicki⁷ and Christie M. Bartels⁸, ¹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hypertension (HTN) is the most prevalent comorbid cardiovascular disease (CVD) risk factor among adults with rheumatic conditions. However, we previously found that high blood…
Abstract Number: 3270 • 2015 ACR/ARHP Annual Meeting
Correction of Limb Length Inequality in Adults with Knee or Hip Symptoms: A Pilot Study
Yvonne M. Golightly¹, Michael T. Gross², Amanda Nelson³, Leigh F. Callahan⁴ and Joanne M. Jordan⁴, ¹Epidemiology, University of North Carolina, Chapel Hill, NC, ²University of North Carolina, Chapel Hill, NC, ³Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ⁴Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC
Background/Purpose: Limb length inequality (LLI; paired lower extremities of unequal length) is associated with knee and hip osteoarthritis (OA) and symptoms consistent with OA (pain,…
Abstract Number: 141 • 2015 ACR/ARHP Annual Meeting
Improved Follow-up of Hypertension in Rheumatology Patients: Results of a Pilot
Christie M. Bartels¹, Edmond Ramly², Heather Johnson³, Yingqi Zhao¹, Zhanhai Li⁴, Patrick McBride³, Kristin Steffen Lewicki¹ and Diane Lauver⁵, ¹Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI, ⁵University of Wisconsin-Madison School of Nursing, Madison, WI
Background/Purpose: Hypertension is the most common and most modifiable cardiovascular disease (CVD) risk factor, yet it is uncontrolled in ½ of US adults. Hypertension management…
Abstract Number: 790 • 2015 ACR/ARHP Annual Meeting
An Intervention to Improve Quality of Life for African-American Lupus Patients
Edith M. Williams¹, Johnese Bostic², Alyssa Adkins³, Larisa Bruner², Jiajia Zhang², Diane L. Kamen⁴ and Jim Oates⁴, ¹Institute for Partnerships to Eliminate Health Disparities, University of South Carolina, Columbia, SC, ²University of South Carolina, Columbia, SC, ³University of South Carolina, Greenville, SC, ⁴Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN) Project is designed to examine whether a uniquely tailored intervention program can…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…
Abstract Number: 2194 • 2015 ACR/ARHP Annual Meeting
Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Alina Casian¹, Shirish Sangle (joint 1st author)², Sotiria Manoustathopoulou³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, UK, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom, ³Department of Medicine, St. Thomas' Hospital, London, United Kingdom, ⁴Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: Our previous data showed renal artery stenosis (RAS) is more prevalent in antiphospholipid syndrome(APS)(26%) compared to the general hypertensive population(8%),and anticoagulation with INR>=3 was…
Abstract Number: 2382 • 2015 ACR/ARHP Annual Meeting
An Outsourced Health-Enhancing Physical Activity Program for People with Rheumatoid Arthritis. Exploration of the Maintenance Phase
Christina H. Opava¹, Birgitta Nordgren¹, Cecilia Fridén¹, Ingrid Demmelmaier¹, Gunnar Bergström², Ingrid E. Lundberg³, Alyssa B. Dufour^1,4, Thomas Nessen¹ and PARA Study Group, ¹Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden, ²Institute of Environmental Medicine, Unit of Intervention and Implementation Research, Karolinska Institutet, Stockholm, Sweden, ³Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Health-enhancing physical activity (HEPA), i.e. at least 150 weekly minutes of moderate-intensity and at least twice-weekly muscle-strengthening activities, is recommended for every adult. Long-term studies on HEPA…
Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting
A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States
Leslie Harrold^1,2, George W. Reed^1,2, J. Timothy Harrington³, Christine J. Barr¹, Katherine C. Saunders¹, Allan Gibofsky⁴, Eric M. Ruderman⁵, Tmirah Haselkorn⁶, Jeffrey D. Greenberg^1,7, Ani John⁶ and Joel M. Kremer⁸, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Joiner Associates, LLC, Madison, WI, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY, ⁸Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
Abstract Number: 1330 • 2014 ACR/ARHP Annual Meeting
The Efficacy of a Multidisciplinary Intervention Strategy for the Treatment of Benign Joint Hypermobility Syndrome (BJHS) in Childhood: A Randomized, Single Center Parallel Group Trial
Peter Bale¹, Vicky Easton², Holly Bacon², Emma Jerman³, Kate Armon⁴ and Alex J Macgregor^1,5, ¹School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom, ²Paediatric Physiotherapy Department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ³Occupational Therapist, Norwich, United Kingdom, ⁴Paediatric Rheumatology, Jenny Lind Children's Hospital, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ⁵Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
Background/Purpose: Joint hypermobility is common in childhood and can be associated with musculoskeletal pain and dysfunction. Current management is delivered by a multidisciplinary team but…
Abstract Number: 1092 • 2014 ACR/ARHP Annual Meeting
Does Arthritis Status Predict Starting or Stopping Work over a 2-Year Period?
Kristina A. Theis¹, Miriam Cisternas² and Louise Murphy³, ¹Athritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²MGC Data Services, San Diego, CA, ³Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose Employment is linked to prosperity, identity, and the ability to contribute to society. Lower employment is well documented among adults with arthritis, but less…
Abstract Number: 885 • 2014 ACR/ARHP Annual Meeting
A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess Safety and Effect Duration
Eric L. Matteson¹, Bhaskar Dasgupta², Wolfgang A. Schmidt³, Carlo Salvarani⁴, Nagui Gendi⁵, Mauro Galeazzi⁶, Sylvie Stitah⁷, Yue Li⁸, Marie-Anne Valentin⁹, Bolan Linghu¹⁰ and Stephen J. Oliver⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Southend University Hospital, Essex, United Kingdom, ³Rheumatology, Immanuel Krankenhaus, Berlin, Germany, ⁴Rheumatology Unit, Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy, ⁵Rheumatology, Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, ⁶Sezione di Reumatologia, Università di Siena, Siena, Italy, ⁷Translational Medicine, Novartis Pharma AG, Basel, Switzerland, ⁸IIS, Novartis Pharma AG, Basel, Switzerland, ⁹Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ¹⁰Translational Medicine, Novartis Pharma AG, Cambridge, MA
Background/Purpose To assess the effects of a single dose of secukinumab or canakinumab in patients with new onset, untreated polymyalgia rheumatica (PMR). Methods In this…
Abstract Number: 2737 • 2013 ACR/ARHP Annual Meeting
In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, Indu Raman⁴, Quan-Zhen Li⁴, John B. Harley^5,6 and Nan Shen^1,2,7, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: New Zealand black and white F1 (NZBW/F1) is a classic mouse model of systemic lupus erythematosus (SLE). Type I interferon (IFN) infusion accelerates lupus…
Abstract Number: 2722 • 2013 ACR/ARHP Annual Meeting
In Vivo Administration Of MiR-146a Protects C57BL/6 Mice From Pristane-Induced Pulmonary Hemorrhage Via Suppressing Type I Interferon Response
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, John B. Harley^4,5 and Nan Shen^1,2,6, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁶Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: miR-146a as an endogenous regulator plays a critical role in resolving acute inflammation. The risk-associated genetic variant in miR-146a promoter was linked to reduced…
Abstract Number: 2091 • 2013 ACR/ARHP Annual Meeting
Adaptation and Preliminary Testing of An Arthritis Walking Program to Reduce Joint Pain for Elderly Breast Cancer Survivors On Aromatase Inhibitor Therapy
Kirsten A. Nyrop¹, Betsy Hackney¹, Rebecca J. Cleveland¹, Mary Altpeter², Hyman Muss³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²UNC Center for Health Promotion and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose: Joint pain/stiffness/achiness (arthralgia) is a common side-effect among postmenopausal women with breast cancer (BC) who are hormone receptor positive (HR+) for whom standard adjuvant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].